CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Buspironedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04807517
NCT04807517Phase 4Completed
CompareCT.gov

Buspirone for the Treatment of Anxiety in Williams Syndrome

Massachusetts General Hospital·interventional·Posted Mar 19, 2021·Updated Dec 3, 2024

In Brief

A Phase 4 clinical trial evaluating Buspirone for Williams Syndrome and Anxiety. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to do a preliminary assessment of whether buspirone is effective, safe, and tolerable in the treatment of anxiety in children, adolescents, and adults with Williams syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWilliams Syndrome, Anxiety
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedMar 19, 2021
Enrollment StartAug 1, 2021
Primary CompletionSep 11, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.3 years ago

Interventions

Buspironedrug

All participants in the study will receive open-label treatment with orally administered buspirone for the full duration of the 16-week trial. Buspirone has high affinity for serotonin 5-HT1A and 5-HT2 receptors and moderate affinity for dopamine D2 receptors. It is approved for the management of generalized anxiety disorder in adults.